

# UCLA

## UCLA Previously Published Works

### Title

Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis

### Permalink

<https://escholarship.org/uc/item/0q835522>

### Journal

Nefrología (English Edition), 41(5)

### ISSN

2013-2514

### Authors

Fabrizi, Fabrizio  
Cerutti, Roberta  
Dixit, Vivek  
[et al.](#)

### Publication Date

2021-09-01

### DOI

10.1016/j.nefro.2021.11.011

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

# Vivek Dixit, Ph.D.

## *Curriculum Vitae*

### PERSONAL INFORMATION

E-MAIL: [vivek.dixit@va.gov](mailto:vivek.dixit@va.gov) | [vdixit@mednet.ucla.edu](mailto:vdixit@mednet.ucla.edu) | [vdixit1@gmail.com](mailto:vdixit1@gmail.com)

### EDUCATION

B.Sc. (Honors) <i>Magna cum Laude</i>	BIOLOGY	1978	Concordia University Montréal, Québec, Canada
M.Sc.	PHYSIOLOGY	1980	McGill University Montréal, Québec, Canada
Ph.D.	PHYSIOLOGY	1986	McGill University Montréal, Québec, Canada

### PROFESSIONAL EXPERIENCE

PRESENT POSITION:	Biologist – Research/Clinical Trials Coordinator United States Department of Veterans Affairs Greater Los Angeles Healthcare System (MAY. 2014 – PRESENT) Adjunct Professor II <i>David Geffen School of Medicine at UCLA, Division of Digestive Diseases.</i> (RE-APPOINTED TO THIS POSITION OCT 2015 – PRESENT)
PREVIOUS POSITIONS:	<u>University of Toronto</u> FRSQ Post-Doctoral Fellow <i>Liver Disease Program, Sunnybrook Medical Centre, University of Toronto</i> <i>Toronto, Canada. JANUARY 1986 - FEBRUARY 1988</i> <u>David Geffen School of Medicine at UCLA, Division of Digestive Diseases.</u> (JANUARY 1988 – NOVEMBER 2005)
Visit. Asst. Researcher	<i>Scientist, Blood-Brain Barrier Laboratory, UCLA School of Medicine, USA</i> FEBRUARY 1988 - MAY 1988
Visit. Asst. Researcher	<i>Scientist, Liver Biosupport and Hepatitis Research Laboratory,</i> MAY 1988 - JUNE 1989
Visit. Asst. Researcher	<i>Scientist, Liver Biosupport and Hepatitis Research Laboratory</i> JULY 1989 - JUNE 1990
Visit. Asst. Researcher	<i>Director of Research, Liver Biosupport and Hepatitis Research Laboratory</i> JULY 1990 - JUNE 1991
Adj. Asst. Researcher IV	<i>Director of Research, Liver Biosupport and Hepatitis Research Laboratory</i> JULY 1991 - JUNE 1993
Adj. Assoc. Professor I	<i>Director of Research, Liver Biosupport and Hepatitis Research Laboratory</i> <i>Co-Director, Basic Science Training Program, Division of Digestive Diseases</i> JULY 1993 - JUNE 1995
Adj. Assoc. Professor II	<i>Director of Research, Liver Biosupport and Hepatitis Research Laboratory</i>

JULY 1995 - JUNE 1997

Adj. Assoc. Professor III *Director of Research, Liver Biosupport and Hepatitis Research Laboratory*  
JULY 1997 - JUNE 2002

Adjunct Professor I *Head, Liver Support and Tissue Engineering Research Laboratory*  
*Department of Medicine, Division of Digestive Diseases.*  
*Private consultant to medical/biotechnology/pharmaceutical industry*  
*and National Science Foundation, SBIR/STTR Review Panelist.*  
JULY 2002 – NOVEMBER 2005 (*retired from UCLA effective Nov 30, 2005*)

Consultant, Sumvaad Corporation, LLC.

CEO, Private consultant to medical/biotechnology/pharmaceutical industry,  
National Science Foundation - SBIR/STTR program, & private venture  
capital. (MARCH 2007 – MAY 2014)

Western University of Health Sciences, Pomona, CA

Part-time Adj. Faculty, Dept. of Physical Therapy (AUG. 2013 – DEC. 2013)

United States Department of Veterans Affairs

Research Scientist – Clinical Trials Coordinator (WOC Appointment)  
Greater Los Angeles Healthcare System (MAY. 2014 – MAY 2015)

## PROFESSIONAL ACTIVITIES

ADMINISTRATIVE RESPONSIBILITIES: Research Director, Liver Support and Tissue Engineering  
Research Lab, Div of Digestive Diseases, UCLA (1988-1993)  
Head, Liver Support and Tissue Engineering Research Laboratory  
Division of Digestive Diseases, UCLA (1993-2005)  
Webmaster, UCLA Division of Digestive Diseases (2002 - 2004)  
Computer skills: Expertise with both Windows and Mac platforms,  
working knowledge of Linux platforms, highly proficient with the  
complete MS Office and similar office productivity software suite,  
database management, CAD and illustration software, statistical  
and mathematics software, website design & management, desktop  
publishing & poster design, and cloud computing.

TEACHING RESPONSIBILITIES: UCLA School of Medicine – teaching & mentoring undergraduate  
and graduate students in physiology/biology, writing scientific  
papers and research grants, scientific research methodologies,  
including light & electron microscopy, tissue culture, and  
development of surgical and drug-induced animal models (small  
and large) for liver and pancreatic diseases in biomedical research  
(since 1986), develop animal models of liver diseases, develop  
novel biomaterials for liver tissue engineering and cell  
transplantation, hepatitis studies and diagnostic methodologies.  
UCLA Cybernetics Program – undergraduate course teaching and

V. Dixit - 2

*Last updated September 2022*

mentoring responsibilities within this joint program between the UCLA School of Medicine and School of Engineering & Computer Sciences (1993-2005)

- RESEARCH ACTIVITIES: U.S. Department of Veterans Affairs, VAGLAHS (2013 – present)-  
CSP577 Study - to investigate the role of FIT testing vs Screening Colonoscopy to identify patients at risk for colorectal cancer.  
VA0036 Study (PI: Pisegna JR)-to investigate the role of a high protein diet on obesity, weight loss and NAFLD.
- NATIONAL SCIENCE FOUNDATION: Member, SBIR/STTR Grant Review Panel (2003 - present)  
Member, Site Visit Team to evaluate GeorgiaTech/Emory Center for Engineering Living Tissues (Year 6 & 7 Renewal; 2004 & 2005)
- SCIENTIFIC PROGRAM COMMITTEE: XI Congress of the International Society for Artificial Cells,  
Blood Substitutes and Immobilization Biotechnology,  
Boston, MA. July 1994  
42nd annual meeting, Am. Soc. for Artif. Intern Organs (1996)  
Co-chairman: Bioartificial Liver Support Devices  
3rd Internet World Congress on Biomedical Sciences,  
Co-chairman: Tissue Engineering & Bioartificial Organs  
Symp. on Tissue Engineering & Bioartificial Organs (1996)  
43rd annual meeting, Am. Soc. for Artif. Intern Organs (1997)  
Chairman, Clinical & Experimental Developments in  
Bioartificial Livers  
3rd World Congress of Biomechanics (1998)  
Co-chairman, Symposium on Artificial Organs  
6th Internet World Congress for Biomedical Sciences  
INABIS 2000, Co-chairman: Tissue Engineering (2000)
- EDITORIAL BOARDS: Cell Transplantation  
Journal of Artificial Cells, Blood Substitutes and  
Immobilization Biotechnology  
International Journal for Artificial Organs
- EDITORIAL SERVICES (REVIEWER): Artificial Organs  
ASAIO Journal  
Cell Transplantation  
Biotechnology & Bioengineering  
Digestive Disease and Science  
Gastroenterology  
Government of Hong Kong, University Grants Commission  
Hepatology  
International Journal for Artificial Organs  
Journal of Artificial Cells, Blood Substitutes and Immobilization  
Biotechnology

Journal of Hepatology  
Journal of Infectious Diseases  
National Science Foundation

SCIENTIFIC SOCIETIES:

American Association for the Study of Liver Diseases (AASLD)  
American Gastroenterological Association (AGA)  
American Society for Artificial Internal Organs (ASAIIO)  
Cell Transplant Society  
AGA - Gastroenterology Research Group  
International Association for the Study of the Liver (IASL)  
International Society for Artificial Cells, Blood Substitutes and  
Immobilization Biotechnology  
International Society for Artificial Organs (ISAO)

VISITING PROFESSORSHIPS:

University of Toronto, Toronto, Canada, October 1985  
McGill University, Montréal, Canada, October 1988  
Thomas Jefferson University, Philadelphia, PA. April 1990  
National Cancer Institute, NIH, Bethesda, MD. April 1990  
University of Washington, Seattle, WA. February 1992  
Hacettepe University, Ankara, Turkey. August 1992  
National Taiwan University, Taipei, Taiwan. 1995.  
Kyoto University, Kyoto, Japan. 1996.  
Ministry of Int'l. Trade and Industry, Govt. of Japan,  
Tsukuba City, Japan. 1997  
Delhi University, G.B. Pant Hospital, New Delhi, India. 1998  
Ankara University, Science Faculty, Ankara, Turkey, 2002.

CONSULTANT/COLLABORATION:

Hacettepe University, Chemical Engineering Department,  
Ankara, Turkey. (with Dr. Erhan Piskin) 1992 to present  
Chiron Corp., Emeryville, CA, USA. (with Dr. A. Polito)  
1993 to 2001.  
Clonetics Corp., San Diego, CA, USA 1994  
HemoCleanse Inc., West Lafayette, IN, USA 1994  
Industrial Technology Research Institute, Chutung, Taiwan.  
(with Dr. Dean-Mo Liu) 1995 to present  
Ankara University, Chemical Engineering Department,  
Ankara, Turkey. (with Dr. Y. Murat Elçin) 1995 to present  
Government of Hong Kong, Univ, Grants Commission, 1996  
HepaHope Inc., Los Angeles, California. (2002-2004)  
National Science Foundation (2003-present)

TEACHING:

UCLA Department of Medicine and Div. of Digestive Diseases  
UCLA Cybernetics Program, Department of Computer Science &  
Bioengineering.  
Western University of Health Sciences, Pomona, CA  
Department of Physical Therapy

**CLINICAL TRIALS – May 2015-Sept. 2018; Jan 2019 - present**

**I WORKED ON THE FOLLOWING CLINICAL TRIALS & OTHER VA STUDIES**

*(Dr. Joseph Pisegna's and Dr. Felix Leung's Research Group, US Dept. of Veterans Affairs)*

1. **Does the Addition of a Cap Improve the Adenoma Detection Rate During Water Exchange Colonoscopy?** – *Clinical Study Coordinator 2019 to present.*  
PI: Dr. Felix Leung
2. **Prospective RCT Of Water Exchange (WE) vs. WE Plus Cap-Assisted Colonoscopy.** – *Clinical Study Coordinator 2019 to present.*  
PI: Dr. Felix Leung
3. **TRPV Receptor Antagonist Modulates Fat Distribution: A Hypothesis –Testing Study in Mice.** – *Research Study Coordinator 2019 to present.*  
PI: Dr. Felix Leung
4. **GI Hormones in Obesity.** – *Study Coordinator since 2015.*  
PI: Dr. Joseph Pisegna
5. **VA Chromogranin A Study.** – *Study Coordinator since 2015.*  
PI: Dr. Joseph Pisegna
6. **Quality of Screening Colonoscopy at a VA Academic Teaching Hospital Compared to a Community Outpatient Facility.** - *Study Coordinator since 2015.*  
PI: Dr. Joseph Pisegna
7. **Effects of Endoscopic Trans-oral Outlet Reduction (TORe) on body weight, oral glucose tolerance and satiety in patients with Roux-en-Y gastric bypass failure and weight regain.**  
*Study Coordinator since 2015.*  
PI: Dr. Joseph Pisegna
8. **CSP #577 Study, Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality from Colorectal Cancer (CONFIRM).** - *Study Coordinator since 2015.*  
LSI: Dr. Joseph Pisegna
9. **A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120mg Plus BSC vs Placebo Plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (SPINET).** - *Study Coordinator since 2016.*  
PI: Dr. Joseph Pisegna
10. **Gene Interactions Relating to Metabolic Syndrome, Obesity and NAFLD in the Million Veteran Program (MVP).** - *Study Coordinator since 2016.*  
PI: Drs. Joseph Pisegna and Jihane Benhammou
11. **COORS: Cirrhosis Outpatient Optimization, Readmissions and Safety TeleHealth Study.**  
*Study Coordinator since 2016. (Study is now completed/closed)*  
PI: Drs. Joseph Pisegna and Christine Yu.
12. **Microbiome, Microbial Markers, & Liver Disease (M<sub>3</sub>LD).** - *Study Coordinator since 2017*  
PI: Drs. Joseph Pisegna and Jonathan Jacobs.

13. **Identification and characterization of risk factors for the development of non-alcoholic fatty liver disease (NAFLD) phenotypes utilizing administrative databases.** - *Study Coordinator since 2017.* PI: Drs. Joseph Pisegna and Jihane Benhammou
14. **Descriptive Study on Veterans with Inflammatory Bowel Disease at the Greater Los Angeles Veterans Affairs.** *Study Coordinator since 2017*  
PI: Drs. Joseph Pisegna and Jonathan Jacobs.
15. **VA Non-Alcoholic Fatty Liver Disease (NAFLD) Study Group** - *Study Coordinator since 2017.*  
PI: Dr. Joseph Pisegna

### **SPECIAL AWARDS AND HONORS**

1. *Magna cum Laude*, B.Sc. Honors, Concordia University, Montréal, Québec, Canada. 1978
2. Faculty of Medicine Award, McGill University, Montréal, Québec, Canada. 1981
3. FCAC - Bourse d'Excellence, Ministry of Education, Govt. of Québec, Canada. 1981 – 1983
4. Faculty of Medicine Award, McGill University, Montréal, Québec, Canada. 1985
5. FRSQ Post-Doctoral Fellowship, Fonds de la Recherche en Santé du Québec  
Ministry of Education, Government of Québec, Canada. 1986 – 1987
6. Member, Liver Disease Program Steering Committee, Sunnybrook Medical Centre  
University of Toronto, Toronto, Ontario, Canada. 1986 – 1987
7. First Sunnybrook Fund Fellowship Award for Medical Research  
Sunnybrook Medical Centre, University of Toronto, Toronto, Ontario, Canada. 1987

### **RESEARCH GRANTS AND FELLOWSHIPS RECEIVED (PEER REVIEWED)**

1. FELLOWSHIP/RESEARCH AWARD: Faculty of Medicine Internal Award  
SOURCE: McGill University, Faculty of Medicine, Montréal, Québec, Canada  
DURATION: 1 Year. 1981
2. FELLOWSHIP: FCAC - Bourse d'Excellence  
SOURCE: Ministry of Education, Government of Québec, Canada.  
DURATION: 3 Years. 1981 – 1983
3. FELLOWSHIP/RESEARCH AWARD: Faculty of Medicine Internal Award  
SOURCE: McGill University, Faculty of Medicine, Montréal, Québec, Canada  
DURATION: 1 Year. 1985
4. FELLOWSHIP: FRSQ Post-Doctoral Fellowship  
SOURCE: Fonds de la Recherche en Santé du Québec, Government of Québec, Canada.  
DURATION: 2 Years. 1986 – 1987
5. FELLOWSHIP: First Sunnybrook Fund Fellowship Award for Medical Research  
SOURCE: Sunnybrook Medical Centre, University of Toronto, Toronto, Ontario, Canada.  
DURATION: 1 Year. 1987
6. GRANT: Towards a Liver Biosupport System  
CO-PRINCIPAL INVESTIGATORS: V. Dixit, Ph.D., M.M. Fisher, M.D., Ph.D.

SOURCE: Physicians' Services Incorporated Foundation, Toronto, Ontario, Canada.  
DURATION: 2 Years. 1987 – 1989

7. GRANT: Development of a Liver Biosupport System  
PRINCIPAL INVESTIGATOR: V. Dixit, Ph.D.  
SOURCE: United Liver Association, Los Angeles, California, USA.  
DURATION: 1 Year. 1988
8. GRANT: Hepatocyte Transplantation in Liver Disease  
PRINCIPAL INVESTIGATOR: V. Dixit, Ph.D.  
SOURCE: United Liver Association, Los Angeles, California, USA.  
DURATION: 1 Year. 1990
9. GRANT: Use of Microcarrier-Attached Hepatocytes in Liver Disease  
CO-PRINCIPAL INVESTIGATORS: E. Piskin, Ph.D., V. Dixit, Ph.D.  
SOURCE: United Liver Association, Los Angeles, California, USA.  
DURATION: 1 Year. 1991
10. GRANT: Development of a Hepatocyte Bioreactor as a Hybrid Bioartificial Liver Support Device  
PRINCIPAL INVESTIGATOR: V. Dixit, Ph.D.  
SOURCE: United Liver Association, Los Angeles, California, USA.  
DURATION: 1 Year. 1992
11. GRANT: Hepatocyte Bioreactor for Artificial Liver Support  
PRINCIPAL INVESTIGATORS: P. Martin, M.D., V. Dixit, Ph.D.  
SOURCE: UCLA Academic Senate, Committee on Research, Los Angeles, California, USA.  
DURATION: 1 Year. 1994
12. GRANT: Evaluation of a New Hepatocyte Bioreactor Using Microencapsulated Porcine Hepatocytes  
PRINCIPAL INVESTIGATOR: S. Biggins, V. Dixit, Ph.D.  
SOURCE: United Liver Association, Los Angeles, California, USA.  
DURATION: 1 Year. 1995
13. GRANT: Tissue Engineering Studies for the Development of Liver Organoids  
PRINCIPAL INVESTIGATOR: D. Friedlich, V. Dixit, Ph.D.  
SOURCE: United Liver Association, Los Angeles, California, USA.  
DURATION: 1 Year. 1995
14. GRANT: Hepatocyte Bioreactor for Liver Support  
PRINCIPAL INVESTIGATOR: V. Dixit, Ph.D.  
SOURCE: Oppenheimer Foundation, Los Angeles, CA.  
DURATION: 1 Year. 1995-1996
15. GRANT: Creation of Liver-Tissue Organoids  
PRINCIPAL INVESTIGATORS: G. Gitnick, M.D., V. Dixit, Ph.D.  
SOURCE: UCLA Academic Senate, Committee on Research, Los Angeles, California, USA.  
DURATION: 1 Year. 1996-1997
16. GRANT: Hepatocyte Bioreactor for Liver Support  
PRINCIPAL INVESTIGATORS: G. Gitnick, M.D., V. Dixit, Ph.D.  
SOURCE: UCLA Academic Senate, Committee on Research, Los Angeles, California, USA.



DURATION: 1 Year. 1997-1998

17. GRANT: Liver Tissue Engineering  
PRINCIPAL INVESTIGATOR: V. Dixit, Ph.D.  
SOURCE: Oppenheimer Foundation, Los Angeles, CA.  
DURATION: 1 Year. 2001-2002
18. GRANT: Evaluation of the HepaHope Bioartificial Liver  
PRINCIPAL INVESTIGATOR: V. Dixit, Ph.D.  
SOURCE: HepaHope, Inc., Los Angeles, CA.  
DURATION: 2 Years. 2002-2004

## INVITED LECTURES

1. *Experimental Studies on Acute Hepatic Failure.*  
University of Toronto, Sunnybrook Medical Centre, Toronto, Ontario, Canada. 1984
2. *Recent Developments in Artificial Liver Support.*  
McGill University, Department of Physiology, Montréal, Québec, Canada. 1988
3. *A Morphologic and Functional Evaluation of Cryopreserved Encapsulated Hepatocytes After Transplantation in Gunn Rats.*  
UCLA, Department of Medicine, Los Angeles, CA. 1989
4. *Artificial Liver Support Systems: Past Experience and Current Concepts.*  
Thomas Jefferson University, Department of Medicine, Philadelphia, PA. 1990
5. *Hepatocyte Transplantation: Current Concepts.*  
National Institutes of Health, National Cancer Institute, Bethesda, MD. 1990
6. *Future of Liver Cell Transplantation in the Management of Liver Disease.*  
United Liver Association, Los Angeles, CA. 1990
7. *Isolated Hepatocytes and Their Potential Use in the Development of an Artificial Liver.*  
National Disease Research Interchange, Washington, DC. 1990
8. *A Liver Machine: Promise for the Future.*  
United Liver Association, Los Angeles, CA. 1991
9. *Liver Cell Transplantation.*  
American Association for the Study of Liver Diseases, Research Workshop, Chicago, IL. 1991
10. *Encapsulation and Culturing of Hepatocytes in Alginate Microcapsules*  
University of Washington, Seattle, WA. 1992
11. *Transplantation of Microencapsulated Cells for Organ Replacement Therapy.*  
Eurobiomat Workshop on Biodegradation and Biodegradable Polymeric Biomaterials, Antalya, Turkey. 1992
12. *Artificial Liver Support: Overview and Current Concepts.*  
Grand Rounds, UCLA Department of Medicine, Los Angeles, CA. 1992
13. *The Rationale of Artificial Liver Support in the Treatment of Fulminant Hepatic Failure.*  
UCLA, Department of Medicine, Hepatology Rounds, Los Angeles, CA. 1993

14. *Development of a Bioartificial Liver Using Isolated Hepatocytes.*  
IXth World Congress of the International Society of Artificial Organs, Amsterdam, The Netherlands. 1993
15. *Artificial Cells Containing Hepatocytes as a Bioartificial Liver.*  
IXth World Congress of the International Society of Artificial Organs, Amsterdam, The Netherlands. 1993
16. *Transplantation of Isolated Hepatocytes and Their Role in Extrahepatic Life Support Systems.*  
Current Topics in Gastroenterology 1993 Symposium, Miami, FL. 1993
17. *Artificial-Cell-Immobilized Hepatocytes As a Bioartificial Liver.*  
XI Congress of the International Society for Artificial Cells and Immobilization Biotechnology, Boston, MA. July 1994
18. *Microencapsulated Hepatocytes.*  
KEYSTONE SYMPOSIUM on Science and Engineering of Immunoprotected Cell Transplants, Frisco, CO. April 1995
19. *Tissue Engineering: A New Dimension.*  
United Liver Association, Los Angeles, CA. 1995.
20. *Hepatocyte Transplantation, Tissue Engineering & Bioartificial Liver -Overview & Recent Developments.*  
National Taiwan University, Taipei, Taiwan. 1995.
21. *Developmental Studies on Bioartificial Liver Support Systems and Liver Organoids Using Fetal Porcine Hepatocytes*  
Xth World Congress of the International Society for Artificial Organs, Taipei, Taiwan. 1995.
22. *Microencapsulated Hepatocytes as a Component of a Bioartificial Liver.*  
23rd International Symposium on Controlled Release of Bioactive Materials, Symposium on Cell Delivery. Controlled Release Society annual meeting, Kyoto, Japan. 1996.
23. *The Engineering of Bioartificial Livers.*  
Kyoto University, 2nd. Department of Surgery, Kyoto, Japan. 1996.
24. *Bioartificial Liver Support Systems.*  
5th National Institute for Advanced Interdisciplinary Research, Ministry of International Trade and Industry, Government of Japan, Tsukuba Science City, Japan. 1997.
25. *Applications of Liver Support Systems.*  
Symposium on the Kidney and Liver in Multi-Organ Failure, Krems (Vienna), Austria. 1997
26. *Use of Embryonal or Fetal Hepatocyte Cultures in Hybrid Liver Support.*  
1997 European Society for Artificial Organs Congress, Budapest, Hungary. 1997
27. *Bioartificial Livers: State-of-the-Art.*  
Current Topics in Gastroenterology, Kona, Hawaii. 1997.
28. *The Bioartificial Liver: Where We Are And Where We're Headed*  
Delhi University, G.B. Pant Hospital Medical Center, New Delhi, India. 1998.
29. *Bioartificial Livers: Current Status and Expectations*  
American Society for Artificial Internal Organs, San Diego, CA, USA. 1999.

30. *Liver Tissue Engineering: Successes and Limitations*  
BioMed 2002 Conference, Antalya, Turkey. 2002.
31. *Bioartificial Livers: Strategies to Treat Liver Diseases*  
Ankara University, Ankara, Turkey. 2002.
32. *In Situ Liver Tissue Engineering in Rodents*  
Hilton Head Tissue Engineering Workshop, Hilton Head, SC. 2002.  
Sponsored by Georgia Tech/Emory Center for the Engineering of Living Tissues.
33. *Current Strategies in the Research and Treatment of Liver Diseases*  
Amrita Institute of Medical Sciences (AIMS), Kochi, Kerala, India. 2007

## PUBLICATIONS/BIBLIOGRAPHY

### RESEARCH PAPERS

#### A. RESEARCH PAPERS: PEER REVIEWED

1. **Dixit V**, Chang TMS. *Soluble liver extract as supplement to detoxification by hemoperfusion in liver failure*. Int J Artif Organs 4(6): 291-294, 1981.
2. **Dixit V**, Chang TMS. *Effects of prostaglandin E<sub>2</sub> on the survival time of fulminant hepatic failure rats*. Int J Artif Organs 5: 388, 1982.
3. **Dixit V**, Chang TMS. *In-vitro and clinical studies on the effects of coated charcoal hemoperfusion on cortisol, thyroxin, insulin, and thyroid-stimulating hormone*. Life Support Systems 2:238-244, 1984.
4. **Dixit V**, Chang TMS. *Preliminary report on the effects of prostaglandin E<sub>2</sub> on brain edema in fulminant hepatic failure rats*. Int J Artif Organs 8(1): 55-56, 1985.
5. **Dixit V**, Chang TMS. *Effects of prostaglandin E<sub>2</sub> on brain edema and liver histopathology in galactosamine-induced fulminant hepatic failure rats*. Biomat Artif Cells Artif Organs 15(3):559-573, 1987.
6. **Dixit V**, Gordon VP, Pappas SC, Fisher MM. *Increased survival in galactosamine induced fulminant hepatic failure in rats following intraperitoneal transplantation of isolated encapsulated hepatocytes*. In Hybrid Artificial Organs, C. Baquey, B. Dupuy eds., Colloque INSERM, Vol. 177, pp. 257-264, 1989.
7. **Dixit V**, Chang TMS. *Brain edema and blood-brain barrier in galactosamine-induced fulminant hepatic failure rats: an animal model for evaluation of liver support systems*. ASAIO Trans 36 (1) 21-27, 1990.
8. **Dixit V**, Darvasi R, Arthur M, Brezina M, Lewin KJ, Gitnick GL. *Restoration of liver function in Gunn rats without immunosuppression using transplanted microencapsulated hepatocytes*. Hepatology 12(6):1342-1349, 1990.
9. **Dixit V**, Arthur M, Reinhardt R, Gitnick G. *Improved function of microencapsulated hepatocytes in a hybrid bioartificial liver support system*. Artif Organs 16(4): 336-341, 1992.
10. **Dixit V**, Arthur M, Gitnick G. *Repeated transplantation of microencapsulated hepatocytes for sustained correction of hyperbilirubinemia in Gunn rats*. Cell Transplantation 1:275-279, 1992.
11. **Dixit V**, Piskin E, Arthur M, Denizli A, Tuncel S, Denkbaz E, Gitnick G. *Hepatocyte immobilization on PHEMA microcarriers and its biologically modified forms*. Cell Transplantation 1:391-399, 1992.
12. **Dixit V**, Arthur M, Gitnick G. *A morphological and functional evaluation of transplanted isolated encapsulated hepatocytes following long-term transplantation in Gunn rats*. Biomat Artif Cells Immob Biotech 21:119-133, 1993.
13. **Dixit V**, Darvasi R, Arthur M, Lewin KJ, Gitnick G. *Cryopreserved microencapsulated hepatocytes: transplantation studies in Gunn rats*. Transplantation 55:616-622, 1993.

14. Ko C, **Dixit V**, Shaw W, Gitnick G. *In vitro slow release profile of endothelial cell growth factor immobilized within calcium alginate microbeads*. *Artif Cells Blood Subst Immob Biotech* 23(2):143-151, 1995.
15. Denizli A, Piskin E, **Dixit V**, Arthur M, Gitnick G. *Collagen and fibronectin immobilization on PHEMA microcarriers for hepatocyte attachment*. *Int J Artif Organs* 18(2):105-110, 1995.
16. **Dixit V**, Quan S, Martin P, Larson D, Brezina M, DiNello R, Sra K, Chen D, Lau JYN, Tagger A, Davis G, Polito A, Gitnick G. *Evaluation of a novel serotyping system for Hepatitis C virus: Strong correlation with standard genotyping methodologies*. *J Clin Microbiol* 33(11):2978-2983, 1995.
17. Elçin YM, **Dixit V**, Gitnick G. *Controlled release of endothelial cell growth factor from chitosan-albumin microspheres for localized angiogenesis: In vitro and in vivo studies* *Artif Cells Blood Subst Immob Biotech* 24(3):257-271, 1996.
18. Ko C, **Dixit V**, Shaw W, Gitnick G. *Extensive in vivo angiogenesis from the controlled release of endothelial cell growth factor: Implication for cell transplantation and wound healing*. *J Controlled Rel* 1997.
19. Martin P, Fabrizi, F, **Dixit V**, Quan S, Brezina M, Kaufman E, Sra K, DiNello R, Polito A, Gitnick G. *Use of automated RIBA hepatitis C virus (HCV) strip immunoblot assay for reproducible HCV diagnosis*. *J Clin Microbiol* 36(2):387-390, 1998.
20. Elçin YM, **Dixit V**, Gitnick G. *Hepatocyte attachment on biodegradable modified chitosan membranes : In vitro evaluation for the development of liver organoids*. *Artif Organs* 22(10): 837-846, 1998.
21. Fabrizi, F, Martin P, **Dixit V**, Brezina M, Cole MJ, Gerosa S, Mousa M, Gitnick G. *Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA (bDNA) signal amplification assay*. *Am J Kid Dis* 31(4): 31(4): 647-54, 1998.
22. Martin P, Fabrizi, F, **Dixit V**, DiNello R, Quan S, Gitnick G. *Quantitative Assessment of HCV Load in Chronic Hemodialysis Patients: A Cross-Sectional Survey*. *Nephron* 80(4): 428-433, 1998.
23. Fabrizi F, Martin P, **Dixit V**, Brezina M, Russell J, Conrad A, Schmid P, Gerosa S, Gitnick G. *Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients*. *Am.J.Nephrol.* 19:383-388, 1999.
24. Elcin YM, **Dixit V**, Lewin K, Gitnick G. *Xenotransplantation of fetal porcine hepatocytes in rats using a tissue engineering approach*. *Artif. Organs* 23:146-152, 1999.
25. Fabrizi F, Martin P, **Dixit V**, Quan S, Brezina M, Abbey H, Gerosa S, Kaufman E, DiNello R, Polito A, Gitnick G. *Epidemiology of Helicobacter pylori in chronic haemodialysis patients using the new RIBA H. pylori SIA*. *Nephrol Dial Transplant* 14(8):1929-33, 1999.
26. Martin P, Fabrizi F, **Dixit V**, Brezina M, Gerosa S, Russell J, Conrad A, Gitnick G. *Epidemiology and natural history of hepatitis G virus infection in chronic hemodialysis patients*. *Am J Nephrol* 19(5):535-40, 1999.
27. Fabrizi F, **V. Dixit**; M. Brezina; M.J. Cole; S. Vinson; M. Mousa; G. Gitnick; P. Martin. *Biological dynamics of viral load in hemodialysis patients with HCV infection: Analysis by branched -chain DNA (bDNA) signal amplification assay*. *Giornale Italiano di Nefrologia* 16(1):48-53, 1999

28. Fabrizi F, Martin P, **Dixit V**, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G. *Biological dynamics of viral load in hemodialysis patients with hepatitis C virus*. Am J Kidney Dis 35(1):122-129, 2000.
29. Fabrizi F, Martin P, Quan S, **Dixit V**, Brezina M, Conrad A, Polito A, Gitnick G. *Serotyping strip immunoblot assay for assessing hepatitis C virus stains in dialysis patients*. Am J Kidney Dis 35(5):832-838, 2000.
30. Martin P, Carter D, Fabrizi F, **Dixit V**, Conrad A, Artinian L, Peacock V, Han S, Wilkinson C, Lassman R, Danovitch G. *Histopathological features of hepatitis C in renal transplant candidates*. Transplantation 69(7):1479-1484, 2000.
31. Fabrizi F, Martin P, **Dixit V**, Quan S, Brezina M, Kaufman E, Sra K, Mousa M, DiNello R, Polito A, Gitnick G. *Automated RIBA HCV strip immunoblot assay: a novel tool for the diagnosis of hepatitis C virus infection in hemodialysis patients*. Am J Nephrology 21(2):104-111, 2001.
32. Elçin YM, **Dixit V**, Gitnick G. *Extensive in vivo angiogenesis from the controlled release of bioactive vascular endothelial cell growth factor: Implications for tissue engineering and wound healing*. Artificial Organs 25 (7):558-565, 2001.
33. Fabrizi F, Dulai G, **Dixit V**, Bunnapradist S, Martin P. *Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients*. Aliment Pharmacol Ther. 18(11-12):1071-1081, 2003.
34. Takimoto Y, **Dixit V**, Arthur M, Gitnick G. *De Novo Liver Tissue Formation in Rats using a Novel Collagen-Polypropylene Scaffold*. Cell Transplant. 12(4):413-21, 2003.
35. Chang AJ, **Dixit V**, Saab S. *Fulminant Hepatic Failure*. Current Treat Options Gastroenterol. 6(6):473-479, 2003.
36. **Dixit V**, Elcin YM. *Liver Tissue Engineering: Successes & Limitations*. Adv Exp Med Biol. 534:57-67. 2003.
37. Fabrizi F, Dulai G, **Dixit V**, Bunnapradist S, Martin P. *Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials*. Transplantation. Transplantation 77(6):859-864, 2004.
38. Fabrizi F, Martin P, **Dixit V**, Bunnapradist S, Dulai G. *Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease*. Aliment Pharmacol Ther. 20(10):1053-1062, 2004.
39. Fabrizi F, Martin P, **Dixit V**, Bunnapradist S, Dulai G. *Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis*. Aliment Pharmacol Ther. 20(11-12):1271-1277, 2004.
40. Fabrizi F, Martin P, **Dixit V**, Bunnapradist S, Dulai G. *Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies*. Am J Transplant. 5(6):1452-1461, 2005.
41. Fabrizi F, Martin P, **Dixit V**, Bunnapradist S, Kanwal F, Dulai G. *Post-transplant Diabetes Mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies*. Am J Transplant. 5(10): 2433-40, 2005.
42. Fabrizi F, Bromberg J, Elli A, **Dixit V**, Martin P. *Hepatitis C virus and calcineurin inhibition after renal transplantation*. Aliment Pharmacol Ther. 22(8):657-666, 2005.

43. Fabrizi F, Martin P, **Dixit V**, Kanwal F, Dulai G. *HBsAg seropositive status and survival after renal transplantation: Meta-Analysis of observational studies*. Am J Transplant. 5(12): 2913–2921, 2005.
44. Fabrizi F, **Dixit V**, Bunnapradist S, Martin P. *Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population*. Aliment Pharmacol Ther. 23(8):1105-1112, 2006.
45. Fabrizi F, **Dixit V**, Martin P. *Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease*. Aliment Pharmacol Ther. 23(11):1559-1566, 2006.
46. Fabrizi F, Mangano S, Aucella F, **Dixit V**, Martin P. *Hepatitis C virus infection and diabetes mellitus in end-stage renal disease: evidence of a negative association*. Int J Artif Organs 29(7):691-697, 2006.
47. Fabrizi F, **Dixit V**, Magnini M, Elli A, Martin P. *Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease*. Aliment Pharmacol Ther. 24(3):497-506, 2006.
48. Fabrizi F, **Dixit V**, Martin P. *Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis*. Aliment Pharmacol Ther. 24(5):781-788, 2006.
49. Fabrizi F, Ganeshan SV, **Dixit V**, Martin P. *Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease*. Aliment Pharmacol Ther. 24(5):789-796, 2006.
50. Fabrizi F, **Dixit V**, Martin P. *Meta-analysis: terlipressin therapy for the hepatorenal syndrome*. Aliment Pharmacol Ther. 24(6):935-944, 2006.
51. Fabrizi F, Lunghi G, **Dixit V**, Martin P. *Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients*. Aliment Pharmacol Ther. 24(10):1413-1422, 2006.
52. Fabrizi F, Bruchfeld A, Mangano S, **Dixit V**, Messa P, Martin P. *Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials*. Int J Artif Organs. 30(3):212-219, 2007.
53. Fabrizi F, Takkouche B, Lunghi G, **Dixit V**, Messa P, Martin P. *The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies*. J Viral Hepat. 14(10):697-703, 2007.
54. Fabrizi F, **Dixit V**, Messa P, Martin P. *Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials*. J Viral Hepat. 15(2):79-88, 2008.
55. Fabrizi F, **Dixit V**, Messa P, Martin P. *Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials*. Int J Artif Organs. 32(3):133-140, 2009.
56. Fabrizi F, **Dixit V**, Messa P, Martin P. *Meta-analysis: Levamisole improves the immune response to hepatitis B vaccine in dialysis patients*. Aliment Pharmacol Ther. 32(6):756-762, 2010.
57. Fabrizio F, Messa P, **Dixit V**, Martin P. *Therapy with nucleos(t)ide analogues: Current role in dialysis patients*. Int J Artif Organs. 33(6):329-338, 2010.

58. Fabrizi F, **Dixit V**, Messa P, Martin P. *Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials.* J Med Virol. 82(5):768-775, 2010.
59. Fabrizi F, **Dixit V**, Martin P, Messa P. *Chronic kidney disease after liver transplantation: Recent evidence.* Int J Artif Organs. 33(11):803-811, 2010.
60. Fabrizi F, **Dixit V**, Martin P, Messa P. *Hepatitis C virus and the immunological response to hepatitis B virus vaccine in dialysis patients: Meta-analysis of clinical studies.* J Viral Hepatitis. 18(12):871-876, 2011.
61. Fabrizi F, **Dixit V**, Messa P, Martin P. *Management of chronic hepatitis B in special populations: Immunosuppressed patients and chronic kidney disease.* Current Hepatitis Reports. 10(4):269-276, 2011.
62. Fabrizi F, **Dixit V**, Messa P, Martin P. *Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: A meta-analysis of randomized trials.* J Viral Hepatitis. 18(10):730-737, 2011.
63. Fabrizi F, **Dixit V**, Martin P, Messa P. *Combined antiviral therapy of hepatitis C virus in dialysis patients: Meta-analysis of clinical trials.* J Viral Hepatitis. 18(7): e236-e269, 2011.
64. Fabrizi F, **Dixit V**, Martin P, Messa P. *Pre-transplant kidney function predicts chronic kidney disease after liver transplant: Meta-analysis of observational studies.* Dig Dis Sci. 56(5):1282-1289, 2011.
65. F. Fabrizi F, **Dixit V**, Martin P, Messa P. *Meta-analysis: The impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients.* Aliment Pharmacol Ther. 33(7):815-821, 2011.
66. Fabrizi F, **Dixit V**, Messa P, Martin P. *Hepatitis C-related liver disease in dialysis patients.* Hep C Renal Dis, Hemodial Transplant. 176:42-53, 2012.
67. Fabrizi F, Jadoul M, **Dixit V**, Messa P, Martin P. *Meta-analysis: The impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease.* Dig Dis Sci. 57(5):1366-1372, 2012. doi: 10.1007/s10620-011-1987-1. Epub 2011 Dec 6. PMID: 22143368
68. Fabrizi F, **Dixit V**, Messa P, Martin P. *Hepatitis C-related liver disease in dialysis patients.* Contribut Nephrol. 176:42-53, 2012. doi: 10.1159/000332379. Epub 2012 Jan 30. PMID: 22310780
69. Fabrizi F, **Dixit V**, Messa P, Martin P. *Hepatitis B virus vaccine in chronic kidney disease: Improved immunogenicity by adjuvants? A meta-analysis of randomized trials.* Vaccine. 30(13):2295-2300, 2012. doi: 10.1016/j.vaccine.2012.01.064. Epub 2012 Jan 26. PMID: 22285268
70. Fabrizi F, Martin P, **Dixit V**, Messa P. *Hepatitis C virus infection and kidney disease: A meta-analysis.* Clin J Am Soc Nephrol. 7(4):549-557, 2012. doi: 10.2215/CJN.06920711. Epub 2012 Mar 8. PMID: 22403269
71. Fabrizi F, **Dixit V**, Martin P, Messa P. *The evidence-based epidemiology of HCV-associated kidney disease.* Int J Artif Organs. 35(9):621-628, 2012. doi: 10.5301/IJAO.2012.9448. PMID: 22886564.
72. Fabrizi F, **Dixit V**, Messa P, Martin P. *Interferon therapy of acute hepatitis C in dialysis patients: Meta-analysis.* J Viral Hep. 19(11):784-791, 2012.



73. Fabrizi F, **Dixit V**, Martin P, Messa P. *Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: A meta-analysis*. *Kid Blood Press Res*. 2013;35(6):504-510, 2013. doi: 10.1159/000335956. Epub 2012 Jul 14. PMID: 22813903
74. Fabrizi F, Dixit V, Messa P. *Interferon mono-therapy for symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies*. *Acta Gastroenterol Belg*. 2013 Dec;76(4):363-71. PMID: 24592538
75. Fabrizi F, Dixit V, Messa P. *Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies*. *J Med Virol*. 2013 Jun;85(6):1019-27. doi: 10.1002/jmv.23562. PMID: 23588727
76. Fabrizi F, Martin P, **Dixit V**, Messa P. *Meta-analysis of observational studies: Hepatitis C and survival after renal transplant*. *J Viral Hep*. 21(5):314-324, 2014.
77. Fabrizi F, **Dixit V**, Martin P, Messa P. *Hepatitis B and survival after renal transplant: Meta-analysis of observational studies*. *J Viral Hep*. 21(8):542-550, 2014.
78. Fabrizi F, **Dixit V**, Messa P, Martin P. *Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: Meta-analysis of clinical studies*. *J Viral Hep*. 21(10):681-689, 2014.
79. Fabrizi F, **Dixit V**, Messa P, Martin P. *Pegylated Interferon Mono-Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta-Analysis*. *Ther Apher Dial*. 2015 Dec;19(6):611-21. doi: 10.1111/1744-9987.12318. Epub 2015 Jul 21. PMID: 26197927
80. Fabrizi F, **Dixit V**, Messa P, Martin P. *Transmission of hepatitis B virus in dialysis units: A systematic review of reports on outbreaks*. *Int J Artif Organs*. 38(1):1-7, 2015. doi: 10.5301/ijao.5000376. Epub 2015 Jan 26. PMID: 25633894.
81. Fabrizi F, **Dixit V**, Martin P, Messa P. *Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis*. *J Med Virol*. 2016 Mar;88(3):487-97. doi: 10.1002/jmv.24353. Epub 2015 Oct. PMID: 26271205
82. Benhammou JN, Dong TS, May FP, Kawamoto J, Dixit R, Jackson S, **Dixit V**, Bhattacharya D, Han SB, Pisegna JR. *Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort*. *Pharmacol Res Perspect*. 2018 Feb 22;6(2):e00379. doi: 10.1002/prp2.379. eCollection 2018 Apr. PMID: 29484189
83. Fabrizi F, **Dixit V**, Piergiorgio M. *Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis*. *Clin Res Hepatol Gastroenterol*. 2019, 43, 244-254. Mar 22. pii: S2210-7401(18)30225-0. <https://doi.org/10.1016/j.clinre.2018.10.009>.
84. Ridruejo E, Garcia-Agudo R, Mendizabal M, Aoufi-Rabih S, Dixit V, Silva M, Fabrizio F. *Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease*. *Nefrología (English Edition)*, Volume 40, Issue 1, January–February 2020, Pages 46-52. <https://doi.org/10.1016/j.nefro.2019.03.013>.

## **B. RESEARCH PAPERS: PEER REVIEWED – IN PREPARATION**

1. Leung F, **Dixit V**, et al. *Does the Addition of a Cap Improve the Adenoma Detection Rate during Water Exchange Colonoscopy?*(data collected;manuscript in preparation).
2. Leung F, **Dixit V**, et al.. *Prospective RCT Of Water Exchange (WE) vs. WE Plus Cap-Assisted Colonoscopy.* ?(data collected; manuscript in preparation).

## **C. RESEARCH PAPERS: PEER REVIEWED – SUBMITTED – NONE**

## **RESEARCH PAPERS (NON PEER REVIEWED)**

### **D. RESEARCH PAPERS: NON-PEER REVIEWED - NONE**

### **E. RESEARCH PAPERS: NON-PEER REVIEWED – IN PRESS- NONE**

### **F. RESEARCH PAPERS: NON-PEER REVIEWED – SUBMITTED- NONE**

## **REVIEWS (PEER REVIEWED)**

1. **Dixit V**. *Development of a bioartificial liver using isolated hepatocytes*. Artif Organs 18:371-384, 1994.
2. **Dixit V**. *Transplantation of isolated hepatocytes and their role in extrahepatic life support systems*. Scand J Gastroenterol 30(208):101-110, 1995.
3. **Dixit V**, Gitnick G. *Transplantation of microencapsulated hepatocytes for liver function replacement*. J Biomater Sci Polymer Edn 7(4):343-357, 1995.
4. **Dixit V**, Gitnick G. *Artificial liver support - State-of-the-art*. Scand J Gastroenterol 31(220):101-114, 1996.
5. **Dixit V**, Gitnick G. *The Bioartificial Liver - State-of-the-art*. Euro J Surg 582:71-76, 1998.
6. **Dixit V**. *Hepatocyte transplantation in liver disease*. J Gastro and Hepatol (Suppl) 14: 2-5, 1999.

## **INVITED RESEARCH PAPERS**

1. **Dixit V**. *Isolated hepatocytes and their potential use in the development of an artificial liver*. Proceedings of the Third International Conference on the Use of Human Cells, Tissues and Organs in Research, NDRI, Washington, DC, USA. pp. 196-199, 1991.
2. **Dixit V**, Biggins S, Gitnick G. *Isolated hepatocytes and their potential use in the development of an artificial liver*. Proceedings of the 23rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan. pp. 8-9, 1996.

## CHAPTERS: PEER REVIEWED

1. **Dixit V**, Gitnick G. *Transplantation of microencapsulated hepatocytes in liver disease*. In: Hepatocyte Transplantation. M. Mito (ed). R.G. Landes Co., Biomedical Publishers, Austin, USA, pp. 78-97, 1997.
2. Ko CY, **Dixit V**, Shaw WW, Gitnick G. *Alginate microbead release assay of angiogenesis*. In: Methods in Molecular Medicine, Vol. 46: Angiogenesis Protocols. J.C. Murray (ed). Humana Press Inc., Totowa, NJ, USA, pp. 53-57, 2000.
3. **Dixit V**, Elcin YM. Liver Tissue Engineering: Successes & Limitations. In: Tissue Engineering, Stem Cells and Gene Therapies, Kluwer Academic/Plenum Publishers, 2003.
4. **Dixit, V**. Hepatocyte Transplantation. In: Transplantation of the Liver. Ronald W Busuttil, MD and Goran B. Klintmalm, eds. W. B. Saunders. 2005.
5. **Dixit V**. Artificial Cells in Liver Disease. In: Artificial Cells, Cell Engineering, and Therapy, Satya Prakash (ed). Woodhead Publishing Limited. 2007.

## BOOKS: PEER REVIEWED

1. Liu D-M, **Dixit V**. Editors. Porous Materials for Tissue Engineering. Trans Tech Publications, Zurich, Switzerland, 1997.

## ABSTRACTS PUBLISHED

1. **Dixit V**, Sherman IA, Fisher MM. *Vesicular transport of bile acids by isolated rat hepatocytes*. Hepatology 6:1131, 1986.
2. **Dixit V**, Trimble CE, Fisher MM. *A liver biosupport system based on isolated encapsulated hepatocytes*. Artif Organs 11(4):311, 1987.
3. **Dixit V**, Gordon VP, Pappas SC, Fisher MM. *Increased survival in GalN-FHF rats following intraperitoneal transplantation of isolated encapsulated hepatocytes*. Biomat Artif Cells Artif Organs 16(4):856, 1988.
4. **Dixit V**, Gordon VP, Pappas SC, Fisher MM. *Transplantation of microencapsulated allogeneic hepatocytes in experimental fulminant hepatic failure: increased survival without immunosuppression*. Hepatology 8(5):1291, 1988.
5. **Dixit V**, Stalnikowicz R, Arthur M, Gitnick G. *A new technique for cryopreservation of hepatocytes*. Gastroenterology 96(5):A594, 1989.
6. **Dixit V**, Stalnikowicz R, Arthur M, Brezina M, Gitnick G. *Transplanted microencapsulated hepatocytes in glucuronyltransferase deficient rats (Gunn) reduce hyperbilirubinemia*. Gastroenterology 96(5):A594, 1989.

7. **Dixit V**, Darvasi R, Arthur M, Lewin K, Gitnick G. *A functional and morphological evaluation of a liver biosupport system based on isolated encapsulated hepatocytes*. *Artif Organs* 13(4):393A, 1989.
8. **Dixit V**, Darvasi R, Arthur M, Lewin KJ, Gitnick G. *A morphological and functional evaluation of cryopreserved isolated encapsulated hepatocytes after transplantation in Gunn rats*. *Hepatology* 10(4):365, 1989.
9. **Dixit V**, Stalnikowicz R, Arthur M, Brezina M, Gitnick G. *Transplantation of isolated encapsulated hepatocytes ameliorates hyperbilirubinemia in Gunn rats*. *Hepatology* 10(4):366, 1989.
10. **Dixit V**, Stalnikowicz R, Arthur M, Brezina M, Gitnick G. *Transplantation of isolated encapsulated hepatocytes corrects hyperbilirubinemia in Gunn rats*. *Clin Res* 38(1):149A, 1990.
11. **Dixit V**, Darvasi R, Arthur M, Lewin K, Gitnick G. *Cryopreserved isolated encapsulated hepatocytes: a morphologic and functional evaluation*. *Clin Res* 38(1):149A, 1990.
12. **Dixit V**, Arthur M, Lewin K, Gitnick G. *Microencapsulation protects hepatocytes from rejection: preliminary long-term studies in Gunn rats*. *Gastroenterology* 98(5):A583, 1990.
13. **Dixit V**, Arthur M, Gitnick G. *Multiple transplantations of microencapsulated hepatocytes for sustained correction of hyperbilirubinemia in Gunn rats*. *Hepatology* 12(4):860, 1990.
14. **Dixit V**, Arthur M, Reinhardt R, Gitnick G. *Synthetic liver basement membrane improves function of transplanted microencapsulated hepatocytes in Gunn rats*. *Clin Res* 39:28A, 1991.
15. **Dixit V**, Arthur M, Reinhardt R, Gitnick G. *Liver cell transplantation: Improved biological response of transplanted microencapsulated hepatocytes with a liver basement membrane-like extract*. *Gastroenterology* 100:A736, 1991.
16. **Dixit V**, Arthur M, Gitnick G. *Demonstration of conjugated bilirubin in bile of Gunn rats with isolated encapsulated hepatocytes*. *Gastroenterology* 100:A736, 1991.
17. **Dixit V**, Arthur M, Reinhardt R, Gitnick G. *Improved function of microencapsulated hepatocytes in a hybrid bioartificial liver support system*. *Artif Organs* 1991;15:272.
18. **Dixit V**, Arthur M, Gitnick G. *Transplanted isolated encapsulated hepatocytes conjugate bilirubin in bile of Gunn rats*. *Hepatology* 14(4): 281A, 1991.
19. **Dixit V**, Piskin E, Arthur M, Denizli A, Tuncel SA, Denkbaz E, Gitnick G. *Hepatocytes on PHEMA microcarriers*. *ASAIO Abstracts* 21: 95, 1992.
20. Piskin E, **Dixit V**, Serbetci AI, Arthur M, Vidrich A, Li R, Gitnick G. *IEC cultures on polyurethane surfaces*. *ASAIO Abstracts* 21: 95, 1992.
21. Piskin E, **Dixit V**, Serbetci AI, Arthur M, Vidrich A, Li R, Gitnick G. *Attachment and growth of intestinal epithelial cells on different polymeric surfaces*. *Gastroenterology* 102(4): A389, 1992.
22. **Dixit V**, Piskin E, Arthur M, Denizli A, Tuncel SA, Denkbaz E, Gitnick G. *Immobilization of hepatocytes on PHEMA microcarriers*. *Gastroenterology* 102(4): A802, 1992.

23. **Dixit V**, Piskin E, Arthur M, Denizli A, Tuncel SA, Denkbaz E, Gitnick G. *Immobilization of hepatocytes on PHEMA microcarriers*. 34th International Union of Pure and Applied Chemistry, International Symposium on Macromolecules, June 13-18, 1992, Prague, Czechoslovakia.
24. Piskin E, **Dixit V**, Serbetci AI, Arthur M, Vidrich A, Li R, Gitnick G. *Attachment and growth of intestinal epithelial cells on different polymeric surfaces*. 34th International Union of Pure and Applied Chemistry, International Symposium on Macromolecules, June 13-18, 1992, Prague, Czechoslovakia.
25. **Dixit V**, Piskin E, Denizli A, Tuncel S, Denkbaz E, Arthur M, Gitnick G. *Hepatocyte immobilization on polymeric microcarriers: a novel tissue engineering concept for a hybrid bioartificial liver*. *Hepatology* 16:51A, 1992.
26. **Dixit V**, Piskin E, Arthur M, Serbetci A, Tuncel S, Gitnick G. *Preliminary studies towards the separation of intestinal epithelial cells from fibroblast contamination with a novel polyfluorostyrene surface*. *Clin Res* 41:85A, 1993.
27. Martin P, Brezina M, DiNello R, **Dixit V**, Polito A, Quan S, Gitnick G. *Enhanced detection of hepatitis C antibodies by modified recombinant immunoblot assay*. Fourth International Symposium on Hepatitis C. May 7-9, 1993, Tokyo, Japan.
28. Martin P, **Dixit V**, Brezina M, Polito A, Quan S, DiNello R, Gitnick G. *Application of a novel recombinant immunoblot assay (RIBA™ SIA) for detection of Hepatitis C infection*. *Gastroenterology* 104:A949, 1993.
29. Martin P, **Dixit V**, Brezina M, Polito A, Quan S, DiNello R, Vallari D, Gitnick G. *Comparison of supplemental specificity assays to detect antibodies to HCV in hemodialysis patients*. *Gastroenterology* 104:A949, 1993.
30. Lucas J, **Dixit V**, Arthur M, Gitnick G. *Splenocyte proliferative response following xenotransplantation of microencapsulated hepatocytes as a bioartificial liver*. *Gastroenterology* 104:A1048, 1993.
31. **Dixit V**, Piskin E, Arthur M, Serbetci A, Tuncel S, Gitnick G. *Application of a novel polyfluorostyrene surface for the separation of intestinal epithelial cells from fibroblast contamination*. *Gastroenterology* 104:A618, 1993.
32. **Dixit V**. *Development of a bioartificial liver using isolated hepatocytes*. *Artif Organs* 17:408, 1993.
33. **Dixit V**. *Artificial cells containing hepatocytes as a bioartificial liver*. *Artif Organs* 17:446, 1993.
34. **Dixit V**, Lucas J, Arthur M, Gitnick G. *Xenotransplantation of microencapsulated hepatocytes as a bioartificial liver: quantitation of splenocyte proliferative response*. *Artif Organs* 17:563, 1993.
35. Piskin E, **Dixit V**, Arthur M, Tuncel A, Gitnick G. *Separation of intestinal cells from fibroblasts with PFS surfaces*. *Artif Organs* 17:536, 1993.
36. Denizli A, **Dixit V**, Arthur M, Denkbaz E, Gitnick G, Piskin E. *Collagen and fibronectin immobilization onto PHEMA microbeads to improve cell attachment*. *Artif Organs* 17:489, 1993.
37. **Dixit V**, Arthur M, Gitnick G. *Immunoisolation of microencapsulated rat hepatocytes following repeated transplantation in guinea pigs: A quantitative assessment*. 9th International Symposium on Microencapsulation, September 13-15, 1993, Ankara, Turkey.

38. **Dixit V**, Piskin E, Denizli A, Kozluca A, Arthur M, Gitnick G. *Preliminary studies on the design of an extracorporeal bioartificial liver support device with tissue engineering technology*. Hepatology 18:329A, 1993.
39. **Dixit V**, Arthur M, Gitnick G. *Quantitative assessment of the immunogenicity of microencapsulated hepatocytes following repeated cross-species transplantations without immunosuppression*. Hepatology 18:66A, 1993.
40. Martin P, Brezina M, **Dixit V**, DiNello R, Quan S, Polito A, Gitnick G. *Acquisition of hepatitis C virus by hemodialysis patients*. Hepatology 18:93A, 1993.
41. **Dixit V**, Piskin E, Denizli A, Kozluca A, Arthur M, Gitnick G. *Design of an extracorporeal bioartificial liver support device: a preliminary study using tissue engineering methodology*. Gastroenterology 106:A884, 1994.
42. **Dixit V**, Gitnick G. *Artificial-cell-immobilized hepatocytes as a bioartificial liver*. Artif Cells Blood Subst Immob Biotech 22:A13, 1994.
43. **Dixit V**, Piskin E, Denizli A, Kozluca A, Arthur M, Gitnick G. *Design of an extracorporeal bioartificial liver support device: a preliminary study using tissue engineering methodology*. 10th World Congresses of Gastroenterology, October 2-7, 1994, Los Angeles, CA, USA.
44. **Dixit V**, Ko C, Shaw W, G. Gitnick. *In vitro slow release profile of endothelial cell growth factor immobilized within calcium alginate microbeads*. J Invest Med 43:195A, 1995.
45. Ko C, **Dixit V**, Shaw W, G. Gitnick. *Sustained release of angiogenic growth factors yields markedly increased in vivo neovascularization*. J Invest Med 43:103A, 1995.
46. **Dixit V**, Biggins S, Martin P, Gitnick G. *A novel hepatocyte bioreactor design for artificial liver support*. J Invest Med 43:148A, 1995.
47. **Dixit V**, Ko C, Shaw W, G. Gitnick. *Calcium alginate microbeads as a vehicle for the controlled release of endothelial cell growth factor for augmented angiogenesis in cell transplantation*. ASAIO Abstracts, 1995.
48. Ko C, **Dixit V**, Shaw W, G. Gitnick. *Enhanced neovascularization by sustained slow release of endothelial cell growth factor for the development of tissue organoids in vivo*. J ASAIO 41(1):88, 1995.
49. **Dixit V**, Biggins S, Martin P, Gitnick G. *The design and preliminary evaluation of a novel extracorporeal bioartificial liver support device*. J ASAIO 41(1):11, 1995.
50. **Dixit V**. *Microencapsulated hepatocytes*. J Cell Biochem 21B:7, 1995.
51. **Dixit V**, Biggins S, Martin P, Gitnick G. *A new extracorporeal bioartificial liver support device: design characteristics and preliminary evaluation*. Gastroenterology 108(4):A1058, 1995.
52. Ko C, **Dixit V**, Shaw W, G. Gitnick. *Rapid and enhanced neovascularization for in vivo development of liver-tissue organoids by sustained slow release of angiogenic growth factor*. Gastroenterology 108(4):A1101, 1995.

53. **Dixit V**, Biggins S, Friedlich D, Arthur M, Martin P, Gitnick G. *Preliminary evaluation of a hemoperfusion-based extracorporeal bioartificial liver support device using fetal porcine hepatocytes*. *Artificial Organs* 19(1):1045, 1995.
54. **Dixit V**, Arthur M, Biggins S, Ko C, Gitnick G. *A simple cost-effective technique for isolating fetal porcine hepatocytes for application in cell transplantation and bioartificial liver support devices*. *Artificial Organs* 19(1):1094, 1995.
55. **Dixit V**, Arthur M, Biggins S, Gitnick G. *Formation of spheroids from isolated fetal porcine hepatocytes for use in bioartificial liver support systems*. *Artificial Organs* 19(1):1045, 1995.
56. **Dixit V**, Biggins S, Friedlich D, Arthur M, Martin P, Gitnick G. *Developmental studies on bioartificial liver support systems and liver organoids using fetal porcine hepatocytes*. *Artificial Organs* 19(1):1016, 1995.
57. Ko C, **Dixit V**, Shaw W, Gitnick G. *Creation of a suitable vascular bed for in vivo cellular and organoid implantation*. *Artificial Organs* 19(1):1050, 1995.
58. Ko C, **Dixit V**, Shaw W, Gitnick G. *Successful xenotransplantation of microencapsulated hepatocytes into the rat fasciovascular groin flap*. *Artificial Organs* 19(1):1023, 1995.
59. Elcin YM, **Dixit V**, Gitnick G. *Controlled release of endothelial cell growth factor from chitosan-albumin microspheres for localized angiogenesis*. *Int J Artif Organs* 18(8):433, 1995.
60. Elcin YM, **Dixit V**, Gitnick G. *Hepatocyte attachment on modified chitosan membranes*. *Int J Artif Organs* 18(8):, 1995.
61. **Dixit V**, Biggins S, Friedlich D, Arthur M, Chen S, Rozga J, Martin P, Demetriou A, Gitnick G. *Preliminary evaluation of a new extracorporeal liver support system in fulminant hepatic failure rats*. *Hepatology* 22(4):212A, 1995.
62. **Dixit V**, Arthur M, Biggins S, Gitnick G. *Isolated fetal porcine hepatocytes: applications in cell transplantation and bioartificial liver support systems*. *Hepatology* 22(4):213A, 1995.
63. **Dixit V**, Quan S, Martin P, Larson D, Brezina M, DiNello R, Sra K, Lau JYN, Chien D, Kolberg J, Tagger A, Davis G, Polito A, Gitnick G. *Evaluation of a novel serotyping system for hepatitis C: strong correlation with standard genotyping methods*. *Hepatology* 22(4):358A, 1995.
64. **Dixit V**, Elcin YM, Lewin K, Gitnick G. *Tissue engineering studies involving xenotransplantation of fetal porcine hepatocytes in rats using biodegradable polymer scaffolds*. *J ASAIO* 42(2):91, 1996.
65. Biggins S, **Dixit V**, Arthur M, Martin P, Chen S, Rozga J, Demetriou A, Gitnick G. *Improved survival of fulminant hepatic failure rats after treatment with the UCLA bioartificial liver support device that utilizes microencapsulated porcine hepatocyte*. *J ASAIO* 42(2):10, 1996.
66. Elcin YM, **Dixit V**, Gitnick G. *Hepatocyte attachment on blended chitosan membranes*. *Gastroenterology* 110(4):A1186, 1996.
67. **Dixit V**, Elcin YM, Lewin K, Arthur M, Gitnick G. *Tissue engineering studies involving xenotransplantation of fetal porcine hepatocytes in rats using biodegradable polymer scaffolds*. *Gastroenterology* 110(4):A1183, 1996.

68. **Dixit V**, Biggins S, Arthur M, Martin P, Chen S, Rozga J, Demetriou A, Gitnick G. *Increased survival of fulminant hepatic failure rats following treatment with the UCLA bioartificial liver support device that utilizes microencapsulated porcine hepatocyte*. Gastroenterology 110(4):A1182, 1996.
69. Quan S, Kaufman E, Sra K, Larson D, DiNello R, **Dixit V**, Brezina M, Martin P, Gitnick G, Polito A. *Automated RIBA™ HCV 2.0 and 3.0 strip immunoblot assay (SIA) testing is as accurate and reliable as manual testing but more user friendly*. Gastroenterology 110(4):A1300, 1996.
70. Martin P, Kleinman S, **Dixit V**, Brezina M, DiNello R, Quan S, Polito A, Shackleton CR, Busuttill RW, Gitnick G. *Prevalence of hepatitis C viral serotypes: comparison of patients with liver disease to blood donors*. Gastroenterology 110(4):A1158, 1996.
71. Martin P, **Dixit V**, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G. *Acquisition of hepatitis C infection in hemodialysis patients: demonstration of de novo infection by branched chain DNA testing*. Gastroenterology 110(4):A1158, 1996.
72. Polito A, Larson D, Sra K, DiNello R, Andrews W, Pichuanes S, Chien D, Kolberg J, Lau JYN, Davis G, **Dixit V**, Brezina M, Martin P, Gitnick G, Cuypers T, Tagger A, Pawlotsky J, Zanella A, Mondelli M, Dow B, Quan S. *A multi-center study of a novel serotyping assay in comparison to PCR based HCV genotype assays*. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome Italy, 1996.
73. Quan S, Kaufman E, Sra K, Larson D, DiNello R, **Dixit V**, Brezina M, Martin P, Gitnick G, Polito A. *Automated RIBA™ HCV 2.0 and 3.0 strip immunoblot assay (SIA) testing is as accurate and reliable as manual testing but more user friendly*. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome Italy, 1996.
74. Martin P, Kleinman S, **Dixit V**, Brezina M, DiNello R, Quan S, Polito A, Shackleton CR, Busuttill RW, Gitnick G. *Prevalence of hepatitis C viral serotypes: comparison of patients with liver disease to blood donors*. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome Italy, 1996.
75. Quan S, Sra K, DiNello R, George-Nascimento C, Brezina M, Kovacs T, Abbey H, **Dixit V**, Martin P, Gitnick G, Polito A. *A novel strip immunoblot assay for the detection of H. pylori infection*. *Helicobacter Pylori: Basic Mechanisms to Clinical Cure*, Ottawa, Canada, 1996.
76. **Dixit V**, Biggins S, Martin P, Arthur M, Gitnick G. *Controlled trials with the UCLA bioartificial liver support device in animals with moderate to severe liver failure*. Hepatology 24(4):436A, 1996.
77. Martin P, Brezina M, **Dixit V**, Russell J, Conrad A, Schmid P, Gitnick G. *Detection of de novo hepatitis C virus by polymerase chain reaction in hemodialysis patients*. Hepatology 24(4):544A, 1996.
78. Lee W.Y, **Dixit V**, Ke B, Arthur M, Biggins S, Imagawa D, Gitnick G. *Effect of UV-B irradiation on adenovirus gene transfer in hepatocytes*. International Symposium on Hepatology, Taipei, Taiwan, (in press), 1996.
79. Lee W.Y, **Dixit V**, Ke B, Arthur M, Biggins S, Imagawa D, Gitnick G. *Effect of UV-B irradiation on adenovirus gene transfer in hepatocytes*. J Invest Med 45(1):162A, 1997.



80. **Dixit V**, Sra K, Yee Jr HF, Quan S, Kovacs T, Abbey H, Brezina M, Martin P, DiNello R, Polito A, Gitnick G. *A new serological test, RIBA™ H. pylori SIA, that improves the detection of H. pylori.* Gastroenterology 112(4):A104, 1997.
81. **Dixit V**, Bettis K, Yee Jr HF, Quan S, Kovacs T, Brezina M, Abbey H, Martin P, DiNello R, Polito A, Gitnick G. *Prevalence of specific ulcer-associated H. pylori antibodies in volunteer and paid blood donors using the new RIBA™ H. pylori SIA.* Gastroenterology 112(4):A104, 1997.
82. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Gitnick G, Martin P. *Hepatitis G virus and other blood bourn viruses in chronic hemodialysis patients.* Gastroenterology 112(4):A1261, 1997.
83. Fabrizi F, Danovitz G, Wilkinson A, **Dixit V**, Brezina M, Stribling R, Artinian L, Russell J, Conrad A, Gitnick G, Martin P. *Histological and virological features of hepatitis C in end-stage renal disease patients presenting for renal transplantation.* Gastroenterology 112(4):A1262, 1997.
84. Lee W.Y, **Dixit V**, Ke B, Arthur M, Biggins S, Imagawa D, Gitnick G. *Adenovirus-mediated gene transfer in hepatocytes: effect of UV-B irradiation.* Gastroenterology 112(4):A1317, 1997.
85. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Schmid P, Gitnick G, Martin P. *Detection of de novo hepatitis C virus (HCV) infection by polymerase chain reaction (PCR) in hemodialysis patients.* ASAIO Journal 43(3):73, 1997.
86. **Dixit V**, Biggins S, Martin P, Arthur M, Gitnick G. *Developmental studies with the UCLA bioartificial liver: controlled trials in animals with varying severity of liver failure.* Artif Organs 21(6):527, 1997.
87. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Martin P, Gitnick G. *Hepatitis G virus and other blood-borne viruses in chronic hemodialysis (HD) patients: an epidemiological evaluation.* Artif Organs 21(6):551, 1997.
88. Fabrizi F, Danovitz G, Wilkinson A, **Dixit V**, Brezina M, Stribling R, Artinian L, Russell J, Conrad A, Gitnick G, Martin P. *Histological and virological features of hepatitis C in end-stage renal disease patients presenting for renal transplantation (RT).* Artif Organs 21(6):551, 1997.
89. **Dixit V**, Dong P, Arthur M, Robert J, Carlson C, Han S, Hoh C, Martin P, Gitnick G. *A unique fluoroscopy-guided model for hepatocyte transplantation: a non-surgical method for treatment of liver failure.* Hepatology 26(4):501, 1997.
90. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Martin P, Gitnick G. *Hepatitis G virus in chronic hemodialysis patients: acquisition and natural history.* Hepatology 26(4):327, 1997.
91. Dong P, **Dixit V**, Arthur M, Robert J, Martin P, Gitnick G. *Non-surgical Intrahepatic Hepatocyte Transplantation with Fluoroscopic Guidance.* J Invest Med 46(1):110A, 1998.
92. Franc B, **Dixit V**, Arthur M, Simon B, Gitnick G. *Flow Dynamics and Metabolic Evaluation of a Packed-Column Bioartificial Liver.* J Invest Med 46(1):110A, 1998.
93. **Dixit V**, Dong P, Arthur M, Robert J, Martin P, Gitnick G. *Percutaneous Intrahepatic Hepatocyte Transplantation with Fluoroscopic Guidance.* Gastroenterology 114(4):L0151, 1998.
94. Franc B, **Dixit V**, Arthur M, Simon B, Gitnick G. *A Packed-Column Bioartificial Liver: Flow Dynamics and Metabolic Evaluation.* Gastroenterology 114(4):L0174, 1998.

95. Martin P, Fabrizi F, **Dixit V**, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. *Biological dynamics of viral load in hemodialysis (HD) patients with hepatitis C virus.* Gastroenterology 114(4):L0400, 1998.
96. Martin P, Fabrizi F, **Dixit V**, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. *Quantitative assessment of HCV load in chronic dialysis patients: a cross-sectional survey,* Gastroenterology 114(4):L0401, 1998.
97. Martin P, Fabrizi F, Quan S, **Dixit V**, Brezina M, Polito A, Gitnick G. *Application of RIBA™-HCV serotyping SIA in hemodialysis patients: a comparison with genotyping assay.* Hepatology 28(4): 280A, 1998.
98. Elçin YM, **Dixit V**, Arthur M, Gitnick G. *Functional characteristics of primary rat hepatocytes in monolayer and on three-dimensional PLGA scaffolds.* Gastroenterology 116(4):L0106, 1999.
99. Elçin YM, **Dixit V**, Arthur M, Gitnick G. *Controlled release of bioactive VEGF for liver tissue engineering.* Gastroenterology 116(4):L0107, 1999.
100. Fabrizi F, Martin P, **Dixit V**, Quan S, Brezina M, Abbey H, Gerosa S, Kaufman E, Polito A, Gitnick G. *Epidemiology of Helicobacter Pylori (HP) in chronic hemodialysis (HD) patients using RIBA HP SIA.* Gastroenterology 116(4):L0681, 1999.
101. Takimoto Y, **Dixit V**, Arthur M, Gitnick G. *Direct evidence of de novo tissue engineered liver in rats transplanted with a collagen-based polypropylene composite scaffold.* Gastroenterology 118(4):2405, 2000.

#### SCIENTIFIC PRESENTATIONS (PEER REVIEWED)

1. **Dixit V**, Sherman IA, Fisher MM. *Vesicular transport of bile acids by isolated rat hepatocytes.* 37th annual meeting of the American Association for the Study of Liver Diseases, November 2-5, 1986, Chicago, IL, USA.
2. **Dixit V**, Trimble CE, Fisher MM. *A liver biosupport system based on isolated encapsulated hepatocytes.* VIth World Congress of the International Society for Artificial Organs and the XIVth Congress of the European Society for Artificial Organs, September 6-9, 1987, Munich, West Germany.
3. **Dixit V**, Gordon VP, Pappas SC, Fisher MM. *Increased survival in GalN-FHF rats following intraperitoneal transplantation of isolated encapsulated hepatocytes.* Biomat 88 Conference on Hybrid Artificial Organs, October 18-19, 1988, Bordeaux, France.
4. **Dixit V**, Stalnikowicz R, Arthur M, Gitnick G. *A new technique for cryopreservation of hepatocytes.* 90th annual meeting of the American Gastroenterological Association, May 13-19, 1989, Washington, DC., USA.
5. **Dixit V**, Darvasi R, Arthur M, Lewin K, Gitnick G. *A functional and morphological evaluation of a liver biosupport system based on isolated encapsulated hepatocytes.* VIIth World Congress of the International Society for Artificial Organs, October 1-4, 1989, Sapporo, Japan.

6. **Dixit V**, Stalnikowicz R, Arthur M, Brezina M, Gitnick G. *Transplantation of isolated encapsulated hepatocytes corrects hyperbilirubinemia in Gunn rats*. Western Society for Clinical Investigation annual meeting, February 6-9, 1990, Carmel, CA, USA.
7. **Dixit V**, Darvasi R, Arthur M, Lewin K, Gitnick G. *Cryopreserved isolated encapsulated hepatocytes: a morphologic and functional evaluation*. Western Society for Clinical Investigation annual meeting, February 6-9, 1990, Carmel, CA, USA.
8. **Dixit V**, Arthur M, Lewin K, Gitnick G. *Microencapsulation protects hepatocytes from rejection: preliminary long-term studies in Gunn rats*. 91st annual meeting of the American Gastroenterological Association, May 13-16, 1990, San Antonio, TX, USA.
9. **Dixit V**, Arthur M, Gitnick G. *Multiple transplantations of microencapsulated hepatocytes for sustained correction of hyperbilirubinemia in Gunn rats*. 41st annual meeting of the American Association for the Study of the Liver, November 5-6, 1990, Chicago, IL, USA.
10. **Dixit V**, Arthur M, Reinhardt R, Gitnick G. *Synthetic liver basement membrane improves function of transplanted microencapsulated hepatocytes in Gunn rats*. Western Society for Clinical Investigation annual meeting, February 6-9, 1991, Carmel, CA, USA.
11. **Dixit V**, Arthur M, Reinhardt R, Gitnick G. *Liver cell transplantation: Improved biological response of transplanted microencapsulated hepatocytes with a liver basement membrane-like extract*. 91st annual meeting of the American Gastroenterological Association, May 19-22, 1991, New Orleans, LA, USA.
12. **Dixit V**, Arthur M, Reinhardt R, Gitnick G. *Improved function of microencapsulated hepatocytes in a hybrid bioartificial liver support system*. VIIIth World Congress of the International Society for Artificial Organs, August 17-23, 1991, Montréal, Québec, Canada.
13. **Dixit V**, Piskin E, Arthur M, Denizli A, Tuncel SA, Denkbaz E, Gitnick G. *Hepatocytes on PHEMA microcarriers*. 38th annual meeting of the American Society for Artificial Internal Organs, May 7-9, 1992, Nashville, TN, USA.
14. Piskin E, **Dixit V**, Serbetci AI, Arthur M, Vidrich A, Li R, Gitnick G. *IEC cultures on polyurethane surfaces*. 38th annual meeting of the American Society for Artificial Internal Organs, May 7-9, 1992, Nashville, TN, USA.
15. Piskin E, **Dixit V**, Serbetci AI, Arthur M, Vidrich A, Li R, Gitnick G. *Attachment and growth of intestinal epithelial cells on different polymeric surfaces*. 92nd annual meeting of the American Gastroenterological Association, May 10-13, 1992, San Francisco, CA, USA.
16. **Dixit V**, Piskin E, Arthur M, Denizli A, Tuncel SA, Denkbaz E, Gitnick G. *Immobilization of hepatocytes on PHEMA microcarriers*. 34th International Union of Pure and Applied Chemistry, International Symposium on Macromolecules, June 13-18, 1992, Prague, Czechoslovakia.
17. **Dixit V**, Piskin E, Denizli A, Tuncel S, Denkbaz E, Arthur M, Gitnick G. *Hepatocyte immobilization on polymeric microcarriers: a novel tissue engineering concept for a hybrid bioartificial liver*. 43rd annual meeting of the American Association for the Study of the Liver, October 31 - November 3, 1992, Chicago, IL, USA.
18. **Dixit V**, Piskin E, Arthur M, Serbetci A, Tuncel S, Gitnick G. *Preliminary studies towards the separation of intestinal epithelial cells from fibroblast contamination with a novel polyfluorostyrene*

*surface*. Western Society for Clinical Investigation annual meeting, February 17-20, 1993, Carmel, CA, USA.

19. Martin P, Brezina M, DiNello R, **Dixit V**, Polito A, Quan S, Gitnick G. *Enhanced detection of hepatitis C antibodies by modified recombinant immunoblot assay*. Fourth International Symposium on Hepatitis C. May 7-9, 1993, Tokyo, Japan.
20. **Dixit V**. *Development of a bioartificial liver using isolated hepatocytes*. IXth World Congress of the International Society for Artificial Organs, July 4-8, 1993, Amsterdam, The Netherlands.
21. **Dixit V**. *Artificial cells containing hepatocytes as a bioartificial liver*. IXth World Congress of the International Society for Artificial Organs, July 4-8, 1993, Amsterdam, The Netherlands.
22. **Dixit V**, Lucas J, Arthur M, Gitnick G. *Xenotransplantation of microencapsulated hepatocytes as a bioartificial liver: quantitation of splenocyte proliferative response*. IXth World Congress of the International Society for Artificial Organs, July 4-8, 1993, Amsterdam, The Netherlands.
23. Piskin E, **Dixit V**, Arthur M, Tuncel A, Gitnick G. *Separation of intestinal cells from fibroblasts with PFS surfaces*. IXth World Congress of the International Society for Artificial Organs, July 4-8, 1993, Amsterdam, The Netherlands.
24. Denizli A, **Dixit V**, Arthur M, Denkbaz E, Gitnick G, Piskin E. *Collagen and fibronectin immobilization onto PHEMA microbeads to improve cell attachment*. IXth World Congress of the International Society for Artificial Organs, July 4-8, 1993, Amsterdam, The Netherlands.
25. **Dixit V**, Arthur M, Gitnick G. *Immunoisolation of microencapsulated rat hepatocytes following repeated transplantation in guinea pigs: A quantitative assessment*. 9th International Symposium on Microencapsulation, September 13-15, 1993, Ankara, Turkey.
26. **Dixit V**. *Transplantation of Isolated Hepatocytes and Their Role in Extrahepatic Life Support Systems*. Current Topics in Gastroenterology 1993, October 31 - November 2, 1993, Miami, FL., USA.
27. **Dixit V**, Arthur M, Gitnick G. *Quantitative assessment of the immunogenicity of microencapsulated hepatocytes following repeated cross-species transplantations without immunosuppression*. 44th annual meeting of the American Association for the Study of the Liver, November 4-7, 1993, Chicago, IL, USA.
28. Martin P, Brezina M, **Dixit V**, DiNello R, Quan S, Polito A, Gitnick G. *Acquisition of hepatitis C virus by hemodialysis patients*. 44th annual meeting of the American Association for the Study of the Liver, November 4-7, 1993, Chicago, IL, USA.
29. **Dixit V**, Gitnick G. *Artificial-Cell-Immobilized Hepatocytes As a Bioartificial Liver*. XI Congress of the International Society for Artificial Cells and Immobilization Biotechnology, Boston, MA. July 24-27, 1994
30. **Dixit V**, Piskin E, Denizli A, Kozluca A, Arthur M, Gitnick G. *Design of an extracorporeal bioartificial liver support device: a preliminary study using tissue engineering methodology*. 10th World Congresses of Gastroenterology, October 2-7, 1994, Los Angeles, CA, USA.

31. Ko C, **Dixit V**, Shaw W, G. Gitnick. *Sustained release of angiogenic growth factors yields markedly increased in vivo neovascularization*. Western Society for Clinical Investigation annual meeting, February 8-11, 1995, Carmel, CA, USA.
32. **Dixit V**, Biggins S, Martin P, Gitnick G. *A novel hepatocyte bioreactor design for artificial liver support*. Western Society for Clinical Investigation annual meeting, February 8-11, 1994, Carmel, CA, USA.
33. **Dixit V**. *Microencapsulated hepatocytes*. Keystone Symposia on Molecular and Cellular Biology: Science and Engineering of Immunoprotected Cell Transplants, April 2-8, 1995, Frisco, CO, USA.
34. Ko C, **Dixit V**, Shaw W, G. Gitnick. *Enhanced neovascularization by sustained slow release of endothelial cell growth factor for the development of tissue organoids in vivo*. American Society for Artificial Internal Organs annual meeting, May 4-6, 1995, Chicago, IL, USA.
35. **Dixit V**, Biggins S, Martin P, Gitnick G. *The design and preliminary evaluation of a novel extracorporeal bioartificial liver support device*. American Society for Artificial Internal Organs annual meeting, May 4-6, 1995, Chicago, IL, USA.
36. **Dixit V**, Biggins S, Martin P, Gitnick G. *A new extracorporeal bioartificial liver support device: design characteristics and preliminary evaluation*. 95th annual meeting of the American Gastroenterological Association, May 14-17, 1995, San Diego, CA, USA.
37. Ko C, **Dixit V**, Shaw W, G. Gitnick. *Rapid and enhanced neovascularization for in vivo development of liver-tissue organoids by sustained slow release of angiogenic growth factor*. 95th annual meeting of the American Gastroenterological Association, May 14-17, 1995, San Diego, CA, USA.
38. Elcin YM, **Dixit V**, Gitnick G. *Controlled release of endothelial cell growth factor from chitosan-albumin microspheres for localized angiogenesis*. 12th Congress of the European Society for Artificial Organs, Berlin, Germany, October 19-21, 1995.
39. Elcin YM, **Dixit V**, Gitnick G. *Hepatocyte attachment on modified chitosan membranes*. 12th Congress of the European Society for Artificial Organs, Berlin, Germany, October 19-21, 1995.
38. **Dixit V**, Biggins S, Friedlich D, Arthur M, Chen S, Rozga J, Martin P, Demetriou A, Gitnick G. *Preliminary evaluation of a new extracorporeal liver support system in fulminant hepatic failure rats*. 46th annual meeting of the American Association for the Study of the Liver, November 3-7, 1995, Chicago, IL, USA.
40. **Dixit V**, Arthur M, Biggins S, Gitnick G. *Isolated fetal porcine hepatocytes: applications in cell transplantation and bioartificial liver support systems*. 46th annual meeting of the American Association for the Study of the Liver, November 3-7, 1995, Chicago, IL, USA.
41. **Dixit V**, Quan S, Martin P, Larson D, Brezina M, DiNello R, Sra K, Lau JYN, Chien D, Kolberg J, Tagger A, Davis G, Polito A, Gitnick G. *Evaluation of a novel serotyping system for hepatitis C: strong correlation with standard genotyping methods*. 46th annual meeting of the American Association for the Study of the Liver, November 3-7, 1995, Chicago, IL, USA.

42. Ko C, **Dixit V**, Shaw W, Gitnick G. *Creation of a suitable vascular bed for in vivo cellular and organoid implantation*. Xth World Congress of the International Society for Artificial Organs, November 14-18, 1995, Teipei, Taiwan.
43. Ko C, **Dixit V**, Shaw W, Gitnick G. *Successful xenotransplantation of microencapsulated hepatocytes into the rat fasciovascular groin flap*. Xth World Congress of the International Society for Artificial Organs, November 14-18, 1995, Teipei, Taiwan.
44. **Dixit V**, Arthur M, Biggins S, Ko C, Gitnick G. *A simple cost-effective technique for isolating fetal porcine hepatocytes for application in cell transplantation and bioartificial liver support devices*. Xth World Congress of the International Society for Artificial Organs, November 14-18, 1995, Teipei, Taiwan.
45. **Dixit V**, Arthur M, Biggins S, Gitnick G. *Formation of spheroids from isolated fetal porcine hepatocytes for use in bioartificial liver support systems*. Xth World Congress of the International Society for Artificial Organs, November 14-18, 1995, Teipei, Taiwan.
46. **Dixit V**, Biggins S, Friedlich D, Arthur M, Martin P, Gitnick G. *Developmental studies on bioartificial liver support systems and liver organoids using fetal porcine hepatocytes*. Xth World Congress of the International Society for Artificial Organs, November 14-18, 1995, Teipei, Taiwan.
47. **Dixit V**, Biggins S, Friedlich D, Arthur M, Martin P, Gitnick G. *Preliminary evaluation of a hemoperfusion-based extracorporeal bioartificial liver support device using fetal porcine hepatocytes*. Xth World Congress of the International Society for Artificial Organs, November 14-18, 1995, Teipei, Taiwan.
48. **Dixit V**, Elcin YM, Lewin K, Gitnick G. *Tissue engineering studies involving xenotransplantation of fetal porcine hepatocytes in rats using biodegradable polymer scaffolds*. 42<sup>nd</sup> annual meeting of the American Society for Artificial Internal Organs, May 2-4, 1996, Washington, DC, USA.
49. Biggins S, **Dixit V**, Arthur M, Martin P, Chen S, Rozga J, Demetriou A, Gitnick G. *Improved survival of fulminant hepatic failure rats after treatment with the UCLA bioartificial liver support device that utilizes microencapsulated porcine hepatocyte*. 42<sup>nd</sup> annual meeting of the American Society for Artificial Internal Organs, May 2-4, 1996, Washington, DC, USA.
50. **Dixit V**, Elcin YM, Lewin K, Arthur M, Gitnick G. *Tissue engineering studies involving xenotransplantation of fetal porcine hepatocytes in rats using biodegradable polymer scaffolds*. 96th annual meeting of the American Gastroenterological Association, May 19-22, 1996, San Diego, CA, USA.
51. **Dixit V**, Biggins S, Arthur M, Martin P, Chen S, Rozga J, Demetriou A, Gitnick G. *Increased survival of fulminant hepatic failure rats following treatment with the UCLA bioartificial liver support device that utilizes microencapsulated porcine hepatocyte*. 96th annual meeting of the American Gastroenterological Association, May 19-22, 1996, San Diego, CA, USA.
52. Quan S, Kaufman E, Sra K, Larson D, DiNello R, **Dixit V**, Brezina M, Martin P, Gitnick G, Polito A. *Automated RIBA™ HCV 2.0 and 3.0 strip immunoblot assay (SIA) testing is as accurate and reliable as manual testing but more user friendly*. 96th annual meeting of the American Gastroenterological Association, May 19-22, 1996, San Diego, CA, USA.

53. Martin P, Kleinman S, **Dixit V**, Brezina M, DiNello R, Quan S, Polito A, Shackleton CR, Busuttill RW, Gitnick G. *Prevalence of hepatitis C viral serotypes: comparison of patients with liver disease to blood donors*. 96th annual meeting of the American Gastroenterological Association, May 19-22, 1996, San Diego, CA, USA.
54. Martin P, **Dixit V**, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G. *Acquisition of hepatitis C infection in hemodialysis patients: demonstration of de novo infection by branched chain DNA testing*. 96th annual meeting of the American Gastroenterological Association, May 19-22, 1996, San Diego, CA, USA.
55. Quan S, Sra K, DiNello R, George-Nascimento C, Brezina M, Kovacs T, Abbey H, **Dixit V**, Martin P, Gitnick G, Polito A. *A novel strip immunoblot assay for the detection of H. pylori infection. Helicobacter Pylori: Basic Mechanisms to Clinical Cure*, June 10-12, 1996, Ottawa, Canada.
56. **Dixit V**, Biggins S, Martin P, Arthur M, Gitnick G. *Controlled trials with the UCLA bioartificial liver support device in animals with moderate to severe liver failure*. 47th annual meeting of the American Association for the Study of the Liver, November 8-12, 1996, Chicago, IL, USA.
57. Lee W.Y, **Dixit V**, Ke B, Arthur M, Biggins S, Imagawa D, Gitnick G. *Effect of UV-B irradiation on adenovirus gene transfer in hepatocytes*. International Symposium on Hepatology, Taipei, Taiwan, Nov. 29 - Dec. 1, 1996.
58. Lee W.Y, **Dixit V**, Ke B, Arthur M, Biggins S, Imagawa D, Gitnick G. *Effect of UV-B irradiation on adenovirus gene transfer in hepatocytes*. Western Society for Clinical Investigation annual meeting, February 5-8, 1997, Carmel, CA, USA.
59. **Dixit V**, Gitnick G. *Developmental studies with the UCLA bioartificial liver*. Bionic Design Workshop, National Institute for Advanced Interdisciplinary Research (NAIR), March 18-19, 1997, Tsukuba, Japan.
60. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Schmid P, Gitnick G, Martin P. *Detection of de novo hepatitis C virus (HCV) infection by polymerase chain reaction (PCR) in hemodialysis patients*. 43<sup>rd</sup> annual meeting of the American Society for Artificial Internal Organs, April 30-May 3, 1997, Atlanta, GA, USA.
61. Fabrizi F, Danovitz G, Wilkinson A, **Dixit V**, Brezina M, Stribling R, Artinian L, Russell J, Conrad A, Gitnick G, Martin P. *Histological and virological features of hepatitis C in end-stage renal disease patients presenting for renal transplantation*. 100th annual meeting of the American Gastroenterological Association, May 10-14, 1997, Atlanta, GA, USA.
62. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Gitnick G, Martin P. *Hepatitis G virus and other blood bourn viruses in chronic hemodialysis patients*. 100th annual meeting of the American Gastroenterological Association, May 10-14, 1997, Atlanta, GA, USA.
63. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Gitnick G, Martin P. *Hepatitis G virus and other blood bourn viruses in chronic hemodialysis patients*. 100th annual meeting of the American Gastroenterological Association, May 10-16, 1997, Washington, DC, USA.
64. Fabrizi F, Danovitz G, Wilkinson A, **Dixit V**, Brezina M, Stribling R, Artinian L, Russell J, Conrad A, Gitnick G, Martin P. *Histological and virological features of hepatitis C in end-stage renal*

*disease patients presenting for renal transplantation.* 100th annual meeting of the American Gastroenterological Association, May 10-16, 1997, Washington, DC, USA.

65. **Dixit V**, Biggins S, Martin P, Arthur M, Gitnick G. *Developmental studies with the UCLA bioartificial liver: controlled trials in animals with varying severity of liver failure.* XIth World Congress of the International Society for Artificial Organs, June 28-July 3, 1997, Providence, RI, USA.
66. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Martin P, Gitnick G. *Hepatitis G virus and other blood-borne viruses in chronic hemodialysis (HD) patients: an epidemiological evaluation.* XIth World Congress of the International Society for Artificial Organs, June 28-July 3, 1997, Providence, RI, USA.
67. Fabrizi F, Danovitz G, Wilkinson A, **Dixit V**, Brezina M, Stribling R, Artinian L, Russell J, Conrad A, Gitnick G, Martin P. *Histological and virological features of hepatitis C in end-stage renal disease patients presenting for renal transplantation (RT).* XIth World Congress of the International Society for Artificial Organs, June 28-July 3, 1997, Providence, RI, USA.
68. Fabrizi F, **Dixit V**, Brezina M, Russell J, Conrad A, Martin P, Gitnick G. *Hepatitis G virus in chronic hemodialysis patients: acquisition and natural history.* 48th annual meeting of the American Association for the Study of the Liver, November 7-11, 1997, Chicago, IL, USA.
69. Dong P, **Dixit V**, Arthur M, Robert J, Martin P, Gitnick G. *Non-surgical Intrahepatic Hepatocyte Transplantation with Fluoroscopic Guidance* Western Society for Clinical Investigation annual meeting, February 4-7, 1998, Carmel, CA, USA.
70. Franc B, **Dixit V**, Arthur M, Simon B, Gitnick G. *Flow Dynamics and Metabolic Evaluation of a Packed-Column Bioartificial Liver.* Western Society for Clinical Investigation annual meeting, February 4-7, 1998, Carmel, CA, USA.
71. **Dixit V**, Dong P, Arthur M, Robert J, Martin P, Gitnick G. *Percutaneous Intrahepatic Hepatocyte Transplantation with Fluoroscopic Guidance.* 101st annual meeting of the American Gastroenterological Association, May 17-20, 1998, New Orleans, LA, USA.
72. Martin P, Fabrizi F, **Dixit V**, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. *Quantitative assessment of HCV load in chronic dialysis patients: a cross-sectional survey,* 101st annual meeting of the American Gastroenterological Association, May 17-20, 1998, New Orleans, LA, USA.
73. Martin P, Fabrizi F, **Dixit V**, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. *Biological dynamics of viral load in hemodialysis (HD) patients with hepatitis C virus.* 101st annual meeting of the American Gastroenterological Association, May 17-20, 1998, New Orleans, LA, USA.
74. Martin P, Fabrizi F, Quan S, **Dixit V**, Brezina M, Polito A, Gitnick G. *Application of RIBA™-HCV serotyping SIA in hemodialysis patients: a comparison with genotyping assay.* 49<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, November 6-10, 1998, Chicago, IL, USA.



75. Elçin YM, **Dixit V**, Arthur M, Gitnick G. *Functional characteristics of primary rat hepatocytes in monolayer and on three-dimensional PLGA scaffolds*. 102nd annual meeting of the American Gastroenterological Association, May 15-19, 1999, Orlando, FL, USA.
76. Elçin YM, **Dixit V**, Arthur M, Gitnick G. *Controlled release of bioactive VEGF for liver tissue engineering*. 102nd annual meeting of the American Gastroenterological Association, May 15-19, 1999, Orlando, FL, USA.
77. Takimoto Y, **Dixit V**, Arthur M, Gitnick G. *Direct evidence of de novo tissue engineered liver in rats transplanted with a collagen-based polypropylene composite scaffold*. 103rd annual meeting of the American Gastroenterological Association, May 21-24, 2000, San Diego, CA, USA.

#### **THESIS PUBLICATIONS**

1. **Dixit V**. *The effect of chilling temperatures on cucumber plants*. B.Sc. Honors Thesis, © V. Dixit, Concordia University, 1978.
2. **Dixit V**. *The effect of ACAC hemoperfusion on the removal of free and protein-bound polypeptides*. M.Sc. Thesis, © V. Dixit, McGill University, 1980.
3. **Dixit V**. *The physiological actions of prostaglandin E<sub>2</sub> on the liver and blood-brain barrier of galactosamine-induced fulminant hepatic failure rats*. Ph.D. Thesis, © V. Dixit, McGill University, 1985.

#### **OTHER INTERESTS AND EXTRACURRICULAR ACTIVITIES**

Cartography, digital photography, 3-D design and simulation software (Maya), modern architecture, ancient Indian history/philosophy/music. Volunteer – American Red Cross.

*A list of references is available on request.*